

Cardiology Research Studies

| Study Name | Criteria for enrollment | Coordinator Contact |
|--|---|--|
| The ATTRACT Study: A phase 3 multicenter, open label study to evaluate the safety of daily oral dosing of tafamidis meglumine (PF-06291826-83) 20mg or 80mg (or tafamidis (PF-06291826-00) 61mg) in subjects diagnosed with transthyretin cardiomyopathy (ATTR-CM) | <ul style="list-style-type: none"> • Diagnosed with amyloidosis and not on tafamidis | <u>Andrew Starovoytov</u> T: 604-875-5079 E: a.starovoytov@ubc.ca |
| BRAIN AF: Blinded Randomized trial of Anticoagulation to prevent Ischemic stroke and Neurocognitive impairment in Atrial Fibrillation | <ul style="list-style-type: none"> • Age at consent ≥ 30 to ≤ 62 years; • Non-valvular atrial fibrillation documented by any electrical heart rhythm testing device in the last 2 years • Low risk of stroke as defined by the absence of all of the following: <ul style="list-style-type: none"> ▪ Prior stroke ▪ High blood pressure ▪ Diabetes ▪ Heart failure | <u>Shirley Lim</u> T: 604-875-4065 E: shirley.lim@vch.ca |
| DIC: Modeling the Functional Impact of Genetic Variants Associated with Doxorubicin-Induced Cardiotoxicity in Genome-edited Isogenic Human Cells | <ul style="list-style-type: none"> • Normal or reduced ejection fraction post doxorubicin treatment | <u>Jackie Chow</u> T: 604-875-5324 E: jackie.chow@vch.ca |
| Invested: Influenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated heart failure | <ul style="list-style-type: none"> • History of at least one of the below events: <ul style="list-style-type: none"> ▪ Hospitalization for heart attack (within one year of visit) ▪ Hospitalization for heart failure (within two years of visit) • At least one of the following: <ul style="list-style-type: none"> ▪ Age ≥ 65 years ▪ Current or historical ejection fraction $< 40\%$ ▪ Type I or type II diabetes ▪ Current BMI ≥ 30 ▪ History of renal impairment ▪ History of ischemic stroke ▪ History of peripheral artery disease ▪ Current tobacco smoker (smokes 1 or more cigarettes daily) | <u>Shirley Lim</u> T: 604-875-4065 E: shirley.lim@vch.ca |
| Prevalence: Multi-center cross-sectional epidemiological study to characterize the prevalence and distribution of lipoprotein(a) levels among patients with established cardiovascular disease | <ul style="list-style-type: none"> • Age 18 to 80 years of age • Established heart disease defined as one of the following: <ul style="list-style-type: none"> ▪ History of heart attack ≥ 3 months and ≤ 10 years ▪ History of ischemic stroke (brain artery blood flow blockage) ≥ 3 months and ≤ 10 years | <u>Naomi Uchida</u> T: 604-875-4521 E: naomi.uchida@ubc.ca <u>Jackie Chow</u> T: 604-875-5324 E: jackie.chow@vch.ca |
| PSVT: Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal | <ul style="list-style-type: none"> • Documented history of Paroxysmal Supraventricular Tachycardia (PSVT) • History of PSVT episodes > 20 minutes | <u>Matthew Wei</u> T: 604-875-5104 E: matthew.wei@vch.ca |

Cardiology Research Studies

| | | |
|--|---|--|
| Supraventricular Tachycardia | | |
| <p>RADICAL PCI: The Role of Androgen Deprivation Therapy In Cardiovascular Disease – A Longitudinal Prostate Cancer Study</p> <p>A Randomized Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2)</p> | <ul style="list-style-type: none"> • 45 years or older • Prostate cancer diagnosis that is either: <ul style="list-style-type: none"> ▪ New (within the last year) ▪ Treated with androgen deprivation therapy (ADT) ▪ To be treated with ADT for the first time within one month | <p><u>Brady Robinson</u> T: 604-875-5106 E: brady.robinson@vch.ca</p> |
| SCAD: Canadian Spontaneous Coronary Artery Dissection | <ul style="list-style-type: none"> • Documented coronary dissection on coronary angiogram | <p><u>Andrew Starovoytov</u> T: 604-875-5079 E: a.starovoytov@ubc.ca</p> |
| Familial hypercholesterolemia (FH) registry | <ul style="list-style-type: none"> • Family or personal history of high cholesterol • Family or personal history of early heart disease (men <55 years, women < 60 years) | <p><u>Tanya Vasyukhnik</u> T: 604-875-5120 E: tanya.vasyukhnik2@vch.ca</p> |
| COAST AF: Characterization of arrhythmia substrate to ablate persistent atrial fibrillation. Randomized clinical trial | <ul style="list-style-type: none"> • Age 19 and 80 years old • Continuous (persistent) atrial fibrillation and will be treated with catheter ablation • At least one documented episode of continuous atrial fibrillation that lasted more than 7 days, but less than three years | <p><u>Tanya Vasyukhnik</u> T: 604-875-5120 E: tanya.vasyukhnik2@vch.ca</p> |
| PREEMPT HF: Precision Event Monitoring for Patients with Heart Failure Using HeartLogic | <ul style="list-style-type: none"> • 18 years of age or older • History of heart failure and a • Received Boston Scientific CRT-D or ICD device implant with HeartLogic sensors | <p><u>Tanya Vasyukhnik</u> T: 604-875-5120 E: tanya.vasyukhnik2@vch.ca</p> |